Importance of controlling diabetes early- the concept of metabolic memory, legacy effect and the case for early insulinisation

Journal of Association of Physicians of India

Volumn 59, Issue SUPPL APRIL2011, 2011, Pages 8-12

  Unnikrishnan, Ranjit I ^a   Anjana, R M ^a   Mohan, V ^a  

^a MADRAS DIABETES RESEARCH FOUNDATION   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84855548232     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Unnikrishnan RI, Rema M, Pradeep R, et al. Prevalence and risk factor of diabetic nephropathy in an urban south Indian population; The Chennai Urban Rural Epidemiology study (CURES-45). Diabetes Care 2007;30:2019-2024.
2. Pradeepa R, Rema M, Vignesh J, Deepa M, Deepa R, Mohan V. Prevalence and risk factors for diabetic neuropathy in an urban south Indian population: The Chennai Urban Rural Epidemiology Study (CURES-55). Diabet Med 2008;25:407-412.
3. Rema M, Premkumar S, Anitha B, Deepa R, Pradeepa R, Mohan V. Prevalence of diabetic retinopathy in urban India: The Chennai Urban Rural Epidemiology Study (CURES) Eye Study I. Invest Ophthalmol Vis Sci 2005;46:2328-2333.
4. Deepa M, Deepa R, Shanthirani CS, et al. Awareness and knowledge of diabetes in Chennai - The Chennai Urban Rural Epidemiology Study (CURES-9). J Assoc Physicians India 2005;53:283-287.
5. Calcutt NA, Cooper ME, Kern TS, Schmidt AM. Therapies for hyperglycemia induced diabetic complications: From animal models to clinical trials. Nat Rev Drug Discov 2009;8:417-429.
6. Zargar AH, Wani AI, Masoodi SR, Laway BA, Bashir MI. Mortality in diabetes mellitus-data from a developing region of the world. Diabetes Res Clin Pract 1999;43:67-74.
7. Mohan V, Shanthirani CS, Deepa M, Deepa R, Unnikrishnan RI, Datta M. Mortality rates due to diabetes in a selected urban south Indian population - The Chennai Urban Population Study (CUPS-16). J Assoc Physicians India 2006;54:113-117.
8. Ramachandran A, Snehalatha C, Satyavani K, Latha E, Sasikala R, Vijay V. Prevalence of vascular complications and their risk factors in type 2 diabetes. J Assoc Physicians India 1999;47:1152-1156.
9. Vijay V, Narasimham DV, Seena R, Snehalatha C, Ramachandran A. Clinical profile of diabetic foot infections in south India--a retrospective study. Diabet Med 2000;17:215-218.
10. Pednekar MS, Gupta R, Gupta PC. Association of blood pressure and cardiovascular mortality in India: Mumbai cohort study. Am J Hypertens 2009;22:1076-1084.
11. Raheja BS, Kapur A, Bhoraskar A, et al. DiabCare Asia-India Study:diabetes care in India-current status. J Assoc Physicians India 2001;49:717-722.
12. Joshi SR, Das AK, Vijay VJ, Mohan V. Challenges in Diabetes Care in India: Sheer Numbers, Lack of Awareness and Inadequate Control. J Assoc Physicians India 2008;56:443-50.
13. Venkataraman K, Kannan AT, Mohan V. Challenges in diabetes management with particular reference to India. Int J Diab Developing Countries 2009;29:103-109.
14. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
15. Writing Team for the Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. J Am Med Assoc 2002;287:2563-2569.
16. Wang PH, Lau J, Chalmers TC. Metaanalysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 1993;341:1306-1309.
17. Raccah D. Importance of blood glucose management in the multifactorial approach of absolute cardiovascular risk in type 2 diabetes: the lessons from the Steno 2 study. Diabetes Metab 2006;32:2S48-51.
18. Colagiuri S, Cull CA, Holman RR, UKPDS Group. Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: UK Prospective Diabetes Study 61. Diabetes Care 2002;25:1410-1417.
19. Patel A, MacMahon S, Chalmers J, et al. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet 2007;370:829-840.
20. Patel A, MacMahon S, Chalmers J, Neal B, et al. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572.
21. Duckworth W, Abraira C, Moritz T, et al. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139.
22. Gerstein HC, Miller ME, Byington RP, et al. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559.
23. Chalmers J, Cooper ME. UKPDS and the legacy effect. N Engl J Med 2008;359:1618-1620.
24. Writing Team for the Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. J Am Med Assoc 2002;287:2563-2569.
25. Gale EA. Glucose control in the UKPDS: what did we learn? Diabet Med 2008;25 Suppl 2:9-12
26. Nathan DM, Cleary PA, Backlund JY, et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-2653.
27. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589.
28. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy with type 1 diabetes four years aftera trial of intensive therapy. N Engl J Med 2000;342:381-389.
29. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus. Arch Ophthalmol 2008;126:1707-1715.
30. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy. JAMA 2003;290:2159-2167.
31. Martin CL, Waberski B, Albers J, et al. Neuropathy among the Diabetes Control and Complications Trial cohort 8 years after trial completion. Diabetes Care 2006;29:340-344.
32. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-2653.
33. Cleary PA, Orchard TJ, Genuth S, et al. DCCT/EDIC Research Group. The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes 2006;55:3556-3565.
34. Goh SY, Cooper ME. Clinical review: The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 2008;93:1143-1152.
35. Ceriello A, Ihnat MA, Thorpe JE. The 'metabolic memory': Is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab 2009;94:410-415.
36. Ihnat MA, Thorpe JE, Ceriello A. Hypothesis: The 'metabolic memory,' the new challenge of diabetes. Diabet Med 2007;24:582-586.
37. Drzewoski J, Kasznicki J, Trojanowski Z. The role of "metabolic memory" in the natural history of diabetes mellitus. Pol Arch Med Wewn 2009;119:493-500.
38. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004;27:17-20.
39. Meneghini L. Why and how to use insulin therapy earlier in the management of type 2 diabetes. South Med J 2007;100:164-74
40. Rask-Madsen C, Ihlemann N, Krarup T, Christiansen E, Kober L, Nervil Kistorp C, Torp-Pedersen C. Insulin therapy improves insulin-stimulated endothelial function in patients with type 2 diabetes and ischemic heart disease. Diabetes 2001;50:2611-18.
41. Chaudhuri A, Kanjwal Y, Mohanty P, Rao S, Sung BH, Wilson MF, Dandona P. Insulin-induced vasodilatation of internal carotid artery. Metabolism 1999;48:1470-1473.
42. Melidonis A, Stefanidis A, Tournis S, Manoussakis S, Handanis S, Zairis M, Dadiotis L, Foussas S. The role of strict metabolic control by insulin infusion on fibrinolytic profile during an acute coronary event in diabetic patients. Clin Cardiol 2000;23:160-164.
43. Chen HS, Wu TE, Jap TS, Hsiao LC, Lee SH, Lin HD. Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care 2008;31:1927-32.
44. DeVries JH, Nattrass M, Pieber TR. Refining basal insulin therapy: what have we learned in the age of analogues? Diabetes Metab Res Rev 2007;23:441-454
45. O'Connor PJ. Improving diabetes care by combating clinical inertia. Health Serv Res 2005;40:1854-1861.